Approval · Notice of Compliance 10027 · 2009
DRAXXIN: Notice of Compliance 10027
Issued February 4, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10027
- Date
- February 4, 2009
- Company
- Pfizer Canada Inc., Animal Health GroupKirkland, Quebec, Canada
- Product type
- Veterinary
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii
- Therapeutic class
- Antibacterial
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DRAXXIN | 02285452 | Marketed |
Medicinal ingredients
- TULATHROMYCIN 100 MG per ML